vadimezan has been researched along with ovalbumin in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (ovalbumin) | Trials (ovalbumin) | Recent Studies (post-2010) (ovalbumin) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 19,565 | 63 | 5,664 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albelda, SM; Blouin, A; Cheng, G; Ching, LM; Jassar, A; Kapoor, V; LaRosa, DF; Sun, J; Wallace, A | 1 |
| Cornwall, SMJ; Graham, PT; Larma, I; Nelson, DJ; Nowak, AK | 1 |
2 other study(ies) available for vadimezan and ovalbumin
| Article | Year |
|---|---|
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chickens; Cytokines; Dendritic Cells; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Necrosis; Neoplasm Transplantation; Ovalbumin; T-Lymphocytes, Cytotoxic; Xanthones | 2007 |
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Disease Models, Animal; Mesothelioma; Mesothelioma, Malignant; Mice; Ovalbumin; T-Lymphocytes, Cytotoxic | 2022 |